Zusammenfassung
Die Einführung der Hochfeld-MRT ermöglicht in der neuroonkologischen Bildgebung bereits im Bereich der T1- und T2-gewichteten Bildgebung eine bessere Darstellung der Tumorstrukturen. Insbesondere aber die suszeptibilitätsgewichtete Bildgebung (SWI) und die Time-of-flight(TOF)-Angiographie profitieren in erhöhtem Maße von der hohen Feldstärke. Die durch die Hochfeldtechnologie mögliche Darstellung der Tumorgefäße in der MRT kann potenziell für das Monitoring antiangiogener Therapien genutzt werden. Zerebrale Metastasen können mit Hilfe der Hochfeldtechnologie potenziell früher entdeckt werden. Weiterhin ermöglicht die Hochfeldtechnologie die Anwendung neuer Techniken wie beispielsweise der Natriumbildgebung, welche einen weiteren Erkenntnisgewinn im Bereich der Tumorpathophysiologie erwarten lassen.
Abstract
The introduction of high-field magnetic resonance imaging (MRI) into neuro-oncological imaging allows improved visualization of tumor structures even in the field of T1 and T2-weighted imaging. Susceptibility-weighted imaging (SWI) and time of flight (TOF) angiography in particular greatly benefit from the high field strength. The visualization of tumor vasculature in MRI, which was made possible by high-field technology can potentially be applied to monitoring antiangiogenic therapy. Cerebral metastases can potentially be discovered earlier using high-field technology. Furthermore, high-field technology permits the use of new technologies, such as sodium imaging, which is expected to provide new information in the field of tumor pathophysiology.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Rees J (2003) Advances in magnetic resonance imaging of brain tumours. Curr Opin Neurol 16(6):643–650
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507
Lupo JM et al (2011) Advances in ultra-high field MRI for the clinical management of patients with brain tumors. Curr Opin Neurol 24(6):605–615
Reichenbach JR, Haacke EM (2001) High-resolution BOLD venographic imaging: a window into brain function. NMR Biomed 14(7–8):453–467
Kim HS et al (2009) Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol 30(8):1574–1579
Radbruch A et al (2012) Differentiation of brain metastases by percentagewise quantification of intratumoral-susceptibility-signals at 3 Tesla. Eur J Radiol, in press
Radbruch A et al (2012) Differentiation of glioblastoma and primary CNS lymphomas using susceptibility weighted imaging. Eur J Radiol, in press
Park MJ et al (2009) Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol 30(7):1402–1408
Di Leva A et al (2013) Three-dimensional susceptibility-weighted imaging at 7 T using fractal-based quantitative analysis to grade gliomas. Neuroradiology 55(1):35–40
Monninghoff C et al (2010) Imaging of brain metastases of bronchial carcinomas with 7 T MRI – initial results. Rofo 182(9):764–772
Lupo JM et al (2012) 7 Tesla susceptibility-weighted imaging to assess the effects of radiotherapy on normal-appearing brain in patients with glioma. Int J Radiat Oncol Biol Phys 82(3):e493–e500
Nowinski WL et al (2013) Comparison of magnetic resonance angiography scans on 1.5, 3, and 7 Tesla units: a quantitative study of 3-dimensional cerebrovasculature. J Neuroimaging 23(1):86–95
Friedman HS et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740
Kreisl TN et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745
Vredenburgh JJ et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259
Plate KH et al (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398):845–848
Grabner G et al (2012) Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. Magn Reson Imaging 30(1):139–147
Di Leva A et al (2012) Fractal analysis of the susceptibility weighted imaging patterns in malignant brain tumors during antiangiogenic treatment: technical report on four cases serially imaged by 7 T magnetic resonance during a period of four weeks. World Neurosurg 77(5–6):785.e11–e21
McKnight TR et al (2001) An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J Magn Reson Imaging 13(2):167–177
Mekle R et al (2009) MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3 T and 7 T. Magn Reson Med 61(6):1279–1285
Srinivasan R et al (2010) Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol 12(11):1152–1161
Nagel AM et al (2011) The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Invest Radiol 46(9):539–547
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seinen Koautor an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Radbruch, A., Schlemmer, HP. Anwendungen der Ultrahochfeld-MRT in der Neuroonkologie. Radiologe 53, 411–414 (2013). https://doi.org/10.1007/s00117-012-2347-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00117-012-2347-7
Schlüsselwörter
- Hochfeldtechnologie
- Glioblastom
- Suszeptibilitätsgewichtete Bildgebung (SWI)
- Time-of-flight(TOF)-Angiographie
- Natriumbildgebung